[HTML][HTML] Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial
…, S Dawson, D Goymer, K Anselmiova… - PLoS …, 2016 - journals.plos.org
Background Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4
+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response …
+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response …
[HTML][HTML] The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
…, J Heywood, J Kennet, EL Arbon, K Anselmiova… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. Type 1 diabetes (T1D) results from loss of immune regulation, leading to
the development of autoimmunity to pancreatic β cells, involving autoreactive T effector cells (…
the development of autoimmunity to pancreatic β cells, involving autoreactive T effector cells (…
[HTML][HTML] Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the …
…, M Evangelou, D Goymer, J Kennet, K Anselmiova… - Trials, 2015 - Springer
Background A barrier to the successful development of new disease treatments is the timely
recruitment of participants to experimental medicine studies that are primarily designed to …
recruitment of participants to experimental medicine studies that are primarily designed to …
Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a response-adaptive, non-randomised, open-label trial of repeat doses of Aldesleukin …
…, J Heywood, J Kennet, EL Arbon, K Anselmiova… - bioRxiv, 2017 - biorxiv.org
Background Type 1 diabetes (T1D) results from loss of immune regulation leading to the
development of autoimmunity to pancreatic beta-cells, involving autoreactive T effector cells (…
development of autoimmunity to pancreatic beta-cells, involving autoreactive T effector cells (…
[PDF][PDF] Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a response-adaptive, non-randomised, open-label trial of repeat doses of …
JK Heywood PhD, K Anselmiova, N Walker, R Atkar… - scholar.archive.org
Background Type 1 diabetes (T1D) results from loss of immune regulation leading to the
development of autoimmunity to pancreatic beta-cells, involving autoreactive T effector cells (…
development of autoimmunity to pancreatic beta-cells, involving autoreactive T effector cells (…
Frequent monitoring of C-peptide levels in newly diagnosed type 1 subjects using dried blood spots collected at home
RH Willemsen, K Burling, P Barker… - The Journal of …, 2018 - academic.oup.com
Objective To evaluate an approach to measure β-cell function by frequent testing of C-peptide
concentrations in dried blood spots (DBSs). Patients Thirty-two children, aged 7 to 17 …
concentrations in dried blood spots (DBSs). Patients Thirty-two children, aged 7 to 17 …
An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice
…, MN Pham, MK Sherve, S Kumari, K Cook… - Science …, 2020 - science.org
Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T (T reg ) cells, and
defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although …
defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although …
Clinical trial characteristics and barriers to participant accrual: The MD Anderson Cancer Center experience over 30 years, a historical foundation for trial improvement
C Tang, SI Sherman, M Price, J Weng, SE Davis… - Clinical Cancer …, 2017 - AACR
Purpose: Slow-accruing clinical trials delay the translation of basic biomedical research,
contribute to increasing health care costs, and may prohibit trials from reaching their original …
contribute to increasing health care costs, and may prohibit trials from reaching their original …
[HTML][HTML] Assessing the effectiveness of Interleukin-2 therapy in experimental type 1 diabetes
Aim Much focus of immunotherapy for type 1 diabetes (T1D) has been devoted on selectively
boosting regulatory T (Treg) cells using low dose IL-2 due to their constitutive expression of …
boosting regulatory T (Treg) cells using low dose IL-2 due to their constitutive expression of …
[HTML][HTML] Early Check: translational science at the intersection of public health and newborn screening
DB Bailey, LM Gehtland, MA Lewis, H Peay, M Raspa… - BMC pediatrics, 2019 - Springer
Background Newborn screening (NBS) occupies a unique space at the intersection of
translational science and public health. As the only truly population-based public health program …
translational science and public health. As the only truly population-based public health program …